KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Long-Term Investments (2016 - 2025)

Astrazeneca (AZN) has 3 years of Long-Term Investments data on record, last reported at $302.0 million in Q4 2025.

  • For Q4 2025, Long-Term Investments fell 81.5% year-over-year to $302.0 million; the TTM value through Dec 2025 reached $302.0 million, down 81.5%, while the annual FY2025 figure was $302.0 million, 81.5% down from the prior year.
  • Long-Term Investments reached $302.0 million in Q4 2025 per AZN's latest filing, down from $1.6 billion in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.6 billion in Q4 2024 and bottomed at $147.0 million in Q4 2023.
  • Average Long-Term Investments over 3 years is $693.7 million, with a median of $302.0 million recorded in 2025.
  • Peak YoY movement for Long-Term Investments: skyrocketed 1010.2% in 2024, then plummeted 81.5% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $147.0 million in 2023, then surged by 1010.2% to $1.6 billion in 2024, then tumbled by 81.5% to $302.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $302.0 million in Q4 2025, $1.6 billion in Q4 2024, and $147.0 million in Q4 2023.